Controversial issues in biliary pancreatitis: When should we perform MRCP and ERCP?

dc.authorid0000-0002-0367-8373en_US
dc.contributor.authorÇavdar, Faruk
dc.contributor.authorTellioğlu, Gürkan
dc.contributor.authorKara, Melih
dc.contributor.authorTilki, Metin
dc.contributor.authorTitiz, Mesut Izzet
dc.contributor.authorYıldar, Murat
dc.date.accessioned2019-10-17T07:36:43Z
dc.date.available2019-10-17T07:36:43Z
dc.date.issued2014en_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionYıldar, Murat (Balikesir author)en_US
dc.description.abstractObjectives: The majority of bile duct stones (BDS) that cause acute binary pancreatitis (ABP) pass spontaneously into the duodenum. If not passed, they worsen the prognosis or cause recurrence. Therefore, they must be treated. The purpose of this study was to assess the number and timing of spontaneous passage of BDS using magnetic resonance cholangiopancreatography (MRCP) and to determine the effect of this approach on endoscopic retrograde cholangiopancreatography (ERCP). Methods: Sixty patients diagnosed with ABP were evaluated prospectively. MRCP was performed between the 1st and 4th days of an acute attack in all the patients. A control MRCP was performed after 7 days in patients with MRCP-identified choledocholithiasis. Patients in whom BDS were visible on imaging or who showed no decrease in bilirubin or cholestasis enzymes underwent ERCP. Results: MRCP revealed choledocholithiasis in 20 (33%) of the 60 patients. In the control MRCP imaging, choledocholithiasis was detected in 16 of 20 (80% of those who had stone initially) patients. ERCP was performed in these patients and in 2 patients who did not have BDS on the control MRCP but whose bilirubin values and cholestatic enzyme levels had not decreased. ERCP verified choledocholithiasis in 16 of the 18 patients. The positive predictive value of MRCP was 93.7% (15/16). Conclusions: MRCP performed in the second week in ABP patients with a nonworsening prognosis and a suspicion of choledocholithiasis will give more specific results. This will avoid unnecessary ERCP and the potential morbidity and mortality that can develop with this invasive procedure. Copyright (C) 2014, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.pan.2014.08.002
dc.identifier.endpage414en_US
dc.identifier.issn1424-3903
dc.identifier.issn1424-3911
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-84906802032
dc.identifier.scopusqualityQ2
dc.identifier.startpage411en_US
dc.identifier.urihttps://doi.org/10.1016/j.pan.2014.08.002
dc.identifier.urihttps://hdl.handle.net/20.500.12462/7658
dc.identifier.volume14en_US
dc.identifier.wosWOS:000342965100018
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofPancreatologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectPancreatitisen_US
dc.subjectCholedocholithiasisen_US
dc.subjectMRCPen_US
dc.subjectERCPen_US
dc.subjectEUSen_US
dc.subjectAcuteen_US
dc.titleControversial issues in biliary pancreatitis: When should we perform MRCP and ERCP?en_US
dc.typeOtheren_US

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
murat-yildar2.pdf
Boyut:
331.21 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: